One bidder and a $5 hike: How Vertex inked $4.9B Alpine deal
Jeffrey Leiden wanted Alpine.
The Vertex chair, who had led early development of the world’s top-selling medicine while at Abbott in the 2000s, had his eyes on Alpine Immune Sciences’ investigational treatment known as povetacicept. The asset “reminds me very much of the potential we saw in Humira in the early days of biologics for the treatment of autoimmune disease,” Leiden told analysts the day of the deal announcement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.